

Willis-Knighton Proton Therapy Center reports a record mean treatment time of 16 minutes per patient

Louvain-la-Neuve, Belgium, 20 October 2018 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, and Willis-Knighton Proton Therapy Center, home of the first compact Intensity Modulated Proton Therapy unit installed in the world, are pleased to announce a record mean time in the treatment room of 16 minutes per patient achieved with the single room Proteus[®]ONE solution. The clinical team at Willis-Knighton Proton Therapy Center has reached workflow excellence while treating a large range of indications, from simple to highly complex cases, such as brain, breast, lung, prostate, central nervous system, gynecological, and gastrointestinal tumors.

Proteus[®]ONE is the only truly compact Image-Guided Intensity Modulated Proton Therapy (IG-IMPT) solution in the industry. It has a unique open gantry designed to ease the work of radiation therapists during treatment through an efficient workflow, optimizing the patient experience with a comfortable and calming environment. Combined with the unique instantaneous oblique imaging system and Cone Beam CT at isocenter, the open gantry enables treatment of a wide range of indications including traditionally difficult cases such as vertex fields for Central Nervous System (CNS) and Head & Neck tumors. Treating non-coplanar fields with an open gantry is easier compared to a less spacious closed gantry.

Olivier Legrain, Chief Executive Officer at IBA, commented: "We are delighted to see our first Proteus[®]ONE clinical partner reaching clinical excellence in the fight against cancer. This accomplishment reinforces the vision we had more than 5 years ago when we launched Proteus[®]ONE to make proton therapy more affordable, quicker to install, and easier to operate. Today's milestone at Willis-Knighton provides confirmation that our open gantry solution is the right choice for proton therapy as a treatment option for the patients."

Lane R. Rosen, MD, Radiation Oncology Medical Director, Willis-Knighton Health System, added: "Our proton therapy center has been a great achievement in the development of cancer care in our community and Louisiana. Using the Proteus[®]ONE solution, our team has treated a diverse group of tumors with a dramatic reduction in treatment related side-effects. Furthermore we have a strong CNS and brain tumor program and with the open gantry we are able to treat a vertex field very easily."





Terry Wu, PhD, Chief of Physics, Willis-Knighton Health System, stated: "The experience accumulated while treating patients in Shreveport over the last 4 years shows that Pencil Beam Scanning Proton Therapy can be safely and efficiently delivered to a wide variety of body sites using both volumetric/CBCT and stereoscopic image-guidance. With a record mean time in the treatment room of 16 minutes per patient and a wide range of indications, the optimized workflow of the Proteus[®]ONE treats up to 20% more patients than other competitive systems."

Download the Proton Therapy Technology Review about the advantages of treating in an open gantry environment : <u>here.</u>

Ends

About Proteus®ONE

Proteus[®]ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus[®]ONE is smaller, more affordable, and easier to install and operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus[®]ONE allows you to think big but scale smart.

*Proteus®ONE is the brand name of a configuration of the Proteus®235.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: <u>www.iba-worldwide.com</u>

Press release | 10/20/2018



Press Release



About Willis-Knighton Cancer Center

The Willis-Knighton Health System, headquartered in Shreveport, Louisiana, is a not-for-profit community healthcare corporation with four general acute care hospitals and affiliate relationships with several rural hospitals. It is the largest nongovernmental employer in the region, employing more than 6,500 people. Specialized centers of excellence include the Willis-Knighton Cancer Center, WK Proton Therapy Center, Willis-Knighton Heart & Vascular Institute, and the WK Rehabilitation Institute, a hospital that incorporates both physical and behavioral rehabilitation. Women's and children's services include maternal/fetal medicine, NICU, and PICU.

http://www.wkhs.com/Cancer/Cancer-Treatment-Services/Proton-Therapy

For further information, please contact:

IBA Daniel Ernult Proton Therapy Marketing Associate Tel +32 10 201 287 communication@iba-group.com

Press release | 10/20/2018

